{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T01:58:04Z","timestamp":1776218284392,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Serbian Ministry of Education","award":["175007"],"award-info":[{"award-number":["175007"]}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clbc.2019.07.007","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T16:55:31Z","timestamp":1566406531000},"page":"e731-e740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis"],"prefix":"10.1016","volume":"19","author":[{"given":"R.T.","family":"Pavlovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Jankovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Milovanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Stefanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.M.","family":"Foli\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.Z.","family":"Milovanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mamillapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.N.","family":"Milosavljevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2019.07.007_bib1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ejmech.2017.11.057","article-title":"Potent aromatase inhibitors and molecular mechanism of inhibitory action","volume":"143","author":"Kang","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.clbc.2019.07.007_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.breast.2013.01.014","article-title":"Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women","volume":"22","author":"Aydiner","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2019.07.007_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2019.07.007_bib4","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/jamaoncol.2016.0429","article-title":"Cardiovascular disease after aromatase inhibitor use","volume":"2","author":"Haque","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2019.07.007_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10549-017-4447-6","article-title":"Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study","volume":"166","author":"Blaes","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2019.07.007_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.breast.2016.01.006","article-title":"Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - meta-analyses on efficacy and adverse events based on randomized clinical trials","volume":"26","author":"Ryd\u00e9n","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2019.07.007_bib7","first-page":"110","article-title":"Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis","author":"Goldvaser","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2019.07.007_bib8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2217\/pgs-2017-0006","article-title":"Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients","volume":"18","author":"Sini","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clbc.2019.07.007_bib9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/annonc\/mds290","article-title":"Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data","volume":"24","author":"Lintermans","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2019.07.007_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.breastdis.2016.07.021","article-title":"The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer","volume":"27","author":"Weitzman","year":"2016","journal-title":"Breast Dis Year B Q"},{"key":"10.1016\/j.clbc.2019.07.007_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/jwh.2017.6515","article-title":"A\u00a0randomized, multicenter, double-blind, study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with vaginal dryness as the most bothersome symptom","volume":"27","author":"Archer","year":"2018","journal-title":"J\u00a0Womens Health (Larchmont)"},{"key":"10.1016\/j.clbc.2019.07.007_bib12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/09513591003632258","article-title":"Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study","volume":"26","author":"Biglia","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.clbc.2019.07.007_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/2053369118805344","article-title":"Managing vulvovaginal atrophy after breast cancer","author":"Sassarini","year":"2018","journal-title":"Post Reprod Health"},{"key":"10.1016\/j.clbc.2019.07.007_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3816\/CBC.2009.n.020","article-title":"Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer","volume":"9","author":"Chin","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2019.07.007_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/sm2.22","article-title":"Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy","volume":"2","author":"Dahir","year":"2014","journal-title":"Sex Med"},{"key":"10.1016\/j.clbc.2019.07.007_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-014-2930-x","article-title":"Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(\u00ae)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study","volume":"145","author":"Donders","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2019.07.007_bib17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/GME.0000000000000613","article-title":"Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial","volume":"23","author":"Fernandes","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2019.07.007_bib18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/GME.0000000000001079","article-title":"Vaginal estrogen and mammogram results: case series and review of literature on treatment of genitourinary syndrome of menopause (GSM) in breast cancer survivors","volume":"25","author":"Zuo","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2019.07.007_bib19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study","volume":"135","author":"Le Ray","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2019.07.007_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/0193945910391483","article-title":"A\u00a0self-report instrument that describes urogenital atrophy symptoms in breast cancer survivors","volume":"34","author":"Lester","year":"2012","journal-title":"West J Nurs Res"},{"key":"10.1016\/j.clbc.2019.07.007_bib21","first-page":"CD001500","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","volume":"8","author":"Lethaby","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clbc.2019.07.007_bib22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2019.07.007_bib23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.maturitas.2010.08.001","article-title":"Women\u2019s voices in the menopause: results from an international survey on vaginal atrophy","volume":"67","author":"Nappi","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2019.07.007_bib24","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","article-title":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society","volume":"20","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2019.07.007_bib25","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2018-01345","article-title":"Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors","volume":"103","author":"Davis","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clbc.2019.07.007_bib26","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","article-title":"Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I\/II study","volume":"16","author":"Witherby","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2019.07.007_bib27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2019.07.007_bib28","series-title":"Meta-analysis in medical research: the handbook for the understanding and practice of meta-analysis","author":"Gioacchino","year":"2005"},{"key":"10.1016\/j.clbc.2019.07.007_bib29","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00404-011-2181-6","article-title":"Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors","volume":"285","author":"Moegele","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.clbc.2019.07.007_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/09513590.2012.705389","article-title":"Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy","volume":"29","author":"Mariani","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.clbc.2019.07.007_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/gme.0b013e31817b6132","article-title":"Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2019.07.007_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/13697130802585576","article-title":"Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview","volume":"12","author":"Al-Baghdadi","year":"2009","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2019.07.007_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/13697137.2017.1329291","article-title":"The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review","volume":"20","author":"Rueda","year":"2017","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2019.07.007_bib34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1210\/endo-96-1-160","article-title":"Estrogen-induced uterine responses and growth: relationship to receptor estrogen binding by uterine nuclei","volume":"96","author":"Anderson","year":"1975","journal-title":"Endocrinology"},{"key":"10.1016\/j.clbc.2019.07.007_bib35","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0032-1314822","article-title":"Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries","volume":"62","author":"Buhling","year":"2012","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clbc.2019.07.007_bib36","first-page":"101","article-title":"Estriol: safety and efficacy","volume":"3","author":"Head","year":"1998","journal-title":"Altern Med Rev"},{"key":"10.1016\/j.clbc.2019.07.007_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.steroids.2012.10.014","article-title":"Estrogen receptor \u03b2 agonists affect growth and gene expression of human breast cancer cell lines","volume":"78","author":"Lattrich","year":"2013","journal-title":"Steroids"},{"issue":"24 Suppl","key":"10.1016\/j.clbc.2019.07.007_bib38","article-title":"Abstract P2-12-05: Limited absorption of low dose 10-\u03bcg intravaginal 17-\u03b2 estradiol (Vagifem\u00ae) in postmenopausal women with breast cancer on aromatase inhibitors","volume":"72","author":"Goldfarb","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2019.07.007_bib39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/13697137.2010.529967","article-title":"Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients","volume":"14","author":"Pfeiler","year":"2011","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2019.07.007_bib40","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2019.07.007_bib41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clbc.2019.07.007_bib42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2147\/IJWH.S52555","article-title":"Reviewing the options for local estrogen treatment of vaginal atrophy","volume":"6","author":"Lindahl","year":"2014","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.clbc.2019.07.007_bib43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/13697137.2011.642427","article-title":"Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients","volume":"15","author":"Kunovac Kallak","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2019.07.007_bib44","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.07.007_bib45","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1158\/0008-5472.CAN-09-3024","article-title":"Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer","volume":"70","author":"Ingle","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2019.07.007_bib46","first-page":"1684","article-title":"Mass spectral analysis of PC-SPES confirms the presence of diethylstilbestrol","volume":"9","author":"Guns","year":"2002","journal-title":"Can J Urol"},{"key":"10.1016\/j.clbc.2019.07.007_bib47","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1055-9965.EPI-07-0028","article-title":"Effect of delays in processing blood samples on measured endogenous plasma sex hormone levels in women","volume":"16","author":"Jones","year":"2007","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.clbc.2019.07.007_bib48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/cmt.6.1.45.52","article-title":"A\u00a0cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer","volume":"6","author":"Dew","year":"2003","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2019.07.007_bib49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1997.4621","article-title":"Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer","volume":"65","author":"Vassilopoulou-Sellin","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2019.07.007_bib50","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/jnci\/djm062","article-title":"Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women","volume":"99","author":"Tamimi","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2019.07.007_bib51","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/1055-9965.EPI-07-0761","article-title":"Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer","volume":"17","author":"Rock","year":"2008","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.clbc.2019.07.007_bib52","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0002-9378(16)32780-6","article-title":"Plasma estriol and its conjugates following oral and vaginal administration of estriol to postmenopausal women: correlations with gonadotropin levels","volume":"138","author":"Schiff","year":"1980","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clbc.2019.07.007_bib53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/00016348309154208","article-title":"Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women","volume":"62","author":"Mattsson","year":"1983","journal-title":"Acta Obstet Gynecol Scand"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820919306512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820919306512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:19:11Z","timestamp":1761513551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820919306512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1526820919306512"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2019.07.007","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2019.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}